Vaccination for preventing XXXX .

@entity1 @entity4094 @entity7794 @entity4091 @entity14000
BACKGROUND: Herpes zoster virus vaccine was recommended for the prevention of @entity4091 and its sequelae by the Advisory Committee on Immunization Practices (ACIP) in 2006. To date the efficacy and safety of vaccination for preventing the most common complication of zoster, @entity14000 , has not been systematically  reviewed. OBJECTIVES: To  assess  the  efficacy  and  safety  of  vaccination in preventing @entity14000 . SEARCH STRATEGY: We searched MEDLINE (January 1966 to December 2010), EMBASE (January 1980 to January 2011), LILACS (January 1982 to December 2010), the Cochrane @entity4094 ( @entity4094 ) Group Specialized Register (10 January 2010), the Cochrane Central Register of Controlled Trials (CENTRAL) (10 January 2010 in the Cochrane Library, Issue 4, 2010) and the Chinese Biomedical Retrieval System (January 1978 to December 2010). We also checked the references of published studies to identify additional trials. SELECTION CRITERIA: We included all randomised  controlled  trials comparing @entity7794 vaccination with placebo, no vaccination or another intervention, irrespective of publication status or language. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality, then extracted and analysed data from the trials which met the inclusion criteria. We collected adverse effects information from the trials. MAIN RESULTS: One trial, which involved 38,546 subjects and compared vaccination with placebo, met our inclusion criteria. This included study was of high quality. However, its @entity1 were all aged 60 years or more and most of them were white, which may mean that its findings are not applicable to all populations. The vaccine was effective in decreasing the incidence of @entity4091 , but there was no evidence that it had efficacy in reducing the incidence of @entity14000 beyond its effect on the incidence of @entity4091 . Adverse events at the injection site were more common among vaccine recipients than placebo recipients, but they were mild and resolved in a few days. Serious adverse events were rare. AUTHORS' CONCLUSIONS: There is insufficient direct evidence from specialised trials to prove the efficacy of vaccine for preventing @entity14000 beyond its effect on reducing @entity4091 , although vaccination may be efficacious and safe for preventing @entity4091 and thus reduce the incidence of @entity14000 in adults aged 60 years or older.
